Page last updated: 2024-12-11

ozenoxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ozenoxacin: an antibacterial for treatment of impetigo; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9863827
CHEMBL ID3990047
CHEBI ID136050
SCHEMBL ID1711829
MeSH IDM000599022

Synonyms (55)

Synonym
CHEBI:136050
ozenoxacin
D09544
xepi (tn)
ozenoxacin (jan/usan/inn)
245765-41-7
gf-001001-00
t-3912
xepi
1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
v0lh498rfo ,
unii-v0lh498rfo
who 8788
ozenoxacin [inn:jan]
ozenoxacin cream
S6582
ozenoxacin [orange book]
1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ozenoxacin [inn]
ozenoxacin [jan]
3-quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-
ozenoxacin [who-dd]
ozenoxacin [usan]
ozenoxacin [mi]
SCHEMBL1711829
t 3912
HY-14957
CS-0003657
DB12924
AKOS032947315
BCP16621
gf-001001-00; m-5120; t-3912; gf-00100100;t3912;t 3912
FT-0701296
EX-A2693
ozenoxacin; t-3912
BS-16742
CHEMBL3990047
Q17125399
SB16801
1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid
gtpl10841
ozadub
NCGC00532517-01
AT18754
ozenoxacin 100 microg/ml in acetonitrile
DTXSID00947446
3-quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-; 1-cyclopropyl-1,4-dihydro-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-8-methyl-7-[5-methy
VJA76541
1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
EN300-19855478
ozenoxacino
d06ax14
ozenoxacine
ozenoxacinum
AC-37196

Research Excerpts

Overview

Ozenoxacin is an excellent candidate for the treatment of bacterial infections caused by susceptible and quinolone-resistant staphylococci isolated usually from skin infections. OzenOxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years.

ExcerptReferenceRelevance
"Ozenoxacin is a new antibiotic used to treat non-bullous impetigo. "( Single-center, prospective, and observational study on the management and treatment of impetigo in a pediatric population.
Capossela, L; Chiaretti, A; Curatola, A; Di Sarno, L; Ferretti, S; Fiori, B; Gatto, A; Oliveti, A; Talamonti, D, 2023
)
2.35
"Ozenoxacin is an excellent candidate for the treatment of bacterial infections caused by susceptible and quinolone-resistant staphylococci isolated usually from skin infections."( Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.
Cantón, R; Gargallo-Viola, D; López, Y; Tato, M; Vila, J; Zsolt, I, 2019
)
1.51
"Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. "( Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
Albareda López, N; Grimalt, R; Masramon, X; Torrelo, A; Zsolt, I, 2020
)
3.44
"Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years."( Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
Albareda López, N; Grimalt, R; Masramon, X; Torrelo, A; Zsolt, I, 2020
)
2.72
"Ozenoxacin is a topical quinolone showing potent antimicrobial activities against Gram-negative and Gram-positive bacteria and is widely used for the treatment of inflammatory acne. "( Anti-inflammatory effects of ozenoxacin, a topical quinolone antimicrobial agent.
Fujikawa, K; Fujikawa, M; Ikeda, F; Kanayama, S; Kitano, T; Matsumoto, T; Mori, S; Nakamura, A; Okamoto, K; Tabara, K; Tamura, R; Uratsuji, H, 2020
)
2.29
"Ozenoxacin is a nonfluorinated quinolone antibacterial approved for topical treatment of impetigo. "( Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs.
Awori, MS; Blazquez, T; Chouinard, L; Gargallo-Viola, D; González Borroto, JI; Smith, SY; Tarragó, C; Zsolt, I, 2018
)
2.16
"Ozenoxacin is a potent antimicrobial agent against staphylococci and streptococci."( Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
Canton, R; García-Castillo, M; Gargallo-Viola, D; López, Y; Morrissey, I; Tato, M; Vila, J; Zsolt, I, 2018
)
2.18
"Ozenoxacin is a novel topical antibacterial agent with potent bactericidal activity against Gram-positive bacteria that has been developed as a 1% cream for treatment of impetigo. "( Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials.
Albareda, N; Grimalt, R; Hebert, AA; Masramon, X; Rosen, T; Rosenberg, N; Torrelo, A; Zsolt, I, 2018
)
1.92
"Ozenoxacin 1% cream is a prescription medicine for topical treatment of impetigo in adults and children 2 months or older."( Topical Ozenoxacin Cream 1% for Impetigo: A Review
Andriessen, A; Bhatia, N; Grada, A; Patele, D; Schachner, L, 2019
)
1.67
"Ozenoxacin is a new des-fluoro-(6)-quinolone active against pathogens involved in skin and skin structure infections, including Gram-positives resistant to fluoroquinolones. "( Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
Cantón, R; Garcia-Alonso, F; Gargallo-Viola, D; López, Y; Moreno-Bofarull, A; Morosini, MI; Tato, M; Vila, J, 2014
)
2.1

Effects

ExcerptReferenceRelevance
"Ozenoxacin has a low probability of selecting spontaneous resistant mutants in quinolone-susceptible or quinolone-resistant bacterial strains and has shown to be active against MRSA isolates."( Topical Ozenoxacin Cream 1% for Impetigo: A Review
Andriessen, A; Bhatia, N; Grada, A; Patele, D; Schachner, L, 2019
)
1.67

Toxicity

The most common treatment-related adverse events were application-site reactions (erythema and pruritus) The differences in local tolerability between ozenoxacin and placebo were not clinically significant.

ExcerptReferenceRelevance
" The most common treatment-related adverse events were application-site reactions (erythema and pruritus), but the differences in local tolerability between ozenoxacin and placebo were not clinically significant."( Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.
Albareda, N; Febbraro, S; Gropper, S; Santos, B, 2014
)
0.84
" Only a few adverse events were reported across repeated-dose studies, and virtually all events were considered to be unrelated or unlikely to be related to ozenoxacin application."( Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers.
Cepero, AL; Dosik, JS; Gropper, S; LaStella, P; Siemetzki, H; Wigger-Alberti, W, 2014
)
0.83
" Ozenoxacin was well tolerated, with 8 of 206 patients experiencing adverse effects, with only 1 of these potentially related to the study treatment; none were serious."( Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
Albareda, N; Alonso, FG; Hebert, AA; Rosen, T; Rosenberg, N; Roth, S; Zsolt, I, 2018
)
1.7

Bioavailability

ExcerptReferenceRelevance
"A series of Phase I studies was conducted in healthy volunteers to examine the systemic bioavailability and safety of topical ozenoxacin."( Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.
Albareda, N; Febbraro, S; Gropper, S; Santos, B, 2014
)
0.85

Dosage Studied

Ozenoxacin concentrations were measured in tape stripping samples (from the stratum corneum) and in skin punch biopsy samples. The cream has a low dosing frequency and a 5 days treatment regimen.

ExcerptRelevanceReference
" Combined with its favorable features, such as a low dosing frequency and a 5 days treatment regimen, ozenoxacin 1% cream is an important option for the treatment of impetigo for pediatric and adult populations."( Topical Ozenoxacin Cream 1% for Impetigo: A Review
Andriessen, A; Bhatia, N; Grada, A; Patele, D; Schachner, L, 2019
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency11.22020.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's28 (73.68)24.3611
2020's10 (26.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.74 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index126.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (21.95%)5.53%
Reviews8 (19.51%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (2.44%)0.25%
Other23 (56.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo [NCT02090764]Phase 3412 participants (Actual)Interventional2014-06-30Completed
A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo [NCT01397461]Phase 3465 participants (Actual)Interventional2012-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01397461 (1) [back to overview]Clinical Success
NCT02090764 (1) [back to overview]Clinical Success

Clinical Success

"Clinical response (clinical success or clinical failure) at end of therapy (Visit 3) in the intent to treat clinical (ITTC) population.~Clinical succes at Visit 3 was defined as: SIRS score 0 for exudates/pus, crusting, tissue warmth and pain and no more than 1 each for erythema/inflammation, tissue edema and itching such that no additional antimicrobial therapy in the baseline (Visit 1) affected area is necessary.~The SIRS is a severity index based on seven signs or symptoms:~Exudate/pus~Crusting~Erythema/inflammation~Tissue warmth~Tissue oedema~Itching~Pain~Each sign/symptom is rated on a scale from 0 to 6:~0 = absent~1 2 = mild 3 4 = moderate 5 6 = severe" (NCT01397461)
Timeframe: 2 weeks

Interventionpercentage of participants (Number)
Ozenoxacin 1% Cream34.8
Ozenoxacin Placebo19.2
Retapamulin 1% Ointment37.7

[back to top]

Clinical Success

"Clinical response (clinical success or clinical failure) at end of therapy (Visit 3) in the intent to treat clinical (ITTC) population.~Clinical success at V3 was defined as: SIRS score 0 for blistering, exudates/pus, crusting and itching/pain and no more than 1 for erythema/inflammation such that no additional antimicrobial therapy in the baseline (Visit 1) affected area is necessary.~The skin infection rating scale (SIRS) is a severity index based on five signs or symptoms: blistering, exudate/pus, crusting, erythema/inflammation, itching/pain." (NCT02090764)
Timeframe: Visit 3 (Day 6-7)

Interventionpercentage of Participants (Number)
Ozenoxacin55.2
Placebo39.2

[back to top]